Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Höllerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU.

Sci Rep. 2017 Sep 13;7(1):11469. doi: 10.1038/s41598-017-11664-5.

2.

Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice.

Rottscholl R, Haegele M, Jainsch B, Xu H, Respondek G, Höllerhage M, Rösler TW, Bony E, Le Ven J, Guérineau V, Schmitz-Afonso I, Champy P, Oertel WH, Yamada ES, Höglinger GU.

J Neurochem. 2016 Nov;139(4):624-639. doi: 10.1111/jnc.13835. Epub 2016 Sep 16.

3.

Neurotoxicity of Dietary Supplements from Annonaceae Species.

Höllerhage M, Rösler TW, Berjas M, Luo R, Tran K, Richards KM, Sabaa-Srur AU, Maia JG, Moraes MR, Godoy HT, Höglinger GU, Smith RE.

Int J Toxicol. 2015 Nov-Dec;34(6):543-50. doi: 10.1177/1091581815602252. Epub 2015 Sep 24.

PMID:
26405269
4.

Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.

Noelker C, Lu L, Höllerhage M, Vulinovic F, Sturn A, Roscher R, Höglinger GU, Hirsch EC, Oertel WH, Alvarez-Fischer D, Andreas H.

J Neurol Sci. 2015 Sep 15;356(1-2):129-36. doi: 10.1016/j.jns.2015.06.030. Epub 2015 Jun 17.

PMID:
26104567
5.

Tau silencing by siRNA in the P301S mouse model of tauopathy.

Xu H, Rösler TW, Carlsson T, de Andrade A, Fiala O, Hollerhage M, Oertel WH, Goedert M, Aigner A, Höglinger GU.

Curr Gene Ther. 2014;14(5):343-51.

PMID:
25687501
6.

Piericidin A aggravates Tau pathology in P301S transgenic mice.

Höllerhage M, Deck R, De Andrade A, Respondek G, Xu H, Rösler TW, Salama M, Carlsson T, Yamada ES, Gad El Hak SA, Goedert M, Oertel WH, Höglinger GU.

PLoS One. 2014 Dec 1;9(12):e113557. doi: 10.1371/journal.pone.0113557. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122907.

7.

Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice.

Xu H, Rösler TW, Carlsson T, de Andrade A, Bruch J, Höllerhage M, Oertel WH, Höglinger GU.

Neuropathol Appl Neurobiol. 2014 Dec;40(7):833-43. doi: 10.1111/nan.12160.

PMID:
24865638
8.

Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity.

Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU.

Neurobiol Aging. 2014 Jul;35(7):1700-11. doi: 10.1016/j.neurobiolaging.2014.01.027. Epub 2014 Jan 28.

PMID:
24559643
9.

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators.

Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824. Epub 2014 Feb 14.

PMID:
24532007
10.

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.

Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T; TAUROS MRI Investigators.

Mov Disord. 2014 Apr;29(4):479-87. doi: 10.1002/mds.25815. Epub 2014 Jan 31.

PMID:
24488721
11.

Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons.

Dolga AM, de Andrade A, Meissner L, Knaus HG, Höllerhage M, Christophersen P, Zischka H, Plesnila N, Höglinger GU, Culmsee C.

Cell Death Dis. 2014 Jan 16;5:e999. doi: 10.1038/cddis.2013.530.

12.

Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice.

Yamada ES, Respondek G, Müssner S, de Andrade A, Höllerhage M, Depienne C, Rastetter A, Tarze A, Friguet B, Salama M, Champy P, Oertel WH, Höglinger GU.

Exp Neurol. 2014 Mar;253:113-25. doi: 10.1016/j.expneurol.2013.12.017. Epub 2014 Jan 3.

13.

Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes.

Li G, Nowak M, Bauer S, Schlegel K, Stei S, Allenhöfer L, Waschbisch A, Tackenberg B, Höllerhage M, Höglinger GU, Wegner S, Wang X, Oertel WH, Rosenow F, Hamer HM.

Seizure. 2013 Jul;22(6):462-6. doi: 10.1016/j.seizure.2013.03.006. Epub 2013 Apr 29.

14.

Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease.

Depboylu C, Höllerhage M, Schnurrbusch S, Brundin P, Oertel WH, Schrattenholz A, Höglinger GU.

Neurosci Lett. 2012 Dec 7;531(2):209-14. doi: 10.1016/j.neulet.2012.10.050. Epub 2012 Nov 2.

PMID:
23123776
15.

Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1.

Rösler TW, Depboylu C, Arias-Carrión O, Wozny W, Carlsson T, Höllerhage M, Oertel WH, Schrattenholz A, Höglinger GU.

Neuropharmacology. 2011 Dec;61(8):1413-8. doi: 10.1016/j.neuropharm.2011.08.033. Epub 2011 Aug 31.

PMID:
21903113
16.

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD.

Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

17.

Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carlsson T, Schindler FR, Höllerhage M, Depboylu C, Arias-Carrión O, Schnurrbusch S, Rösler TW, Wozny W, Schwall GP, Groebe K, Oertel WH, Brundin P, Schrattenholz A, Höglinger GU.

J Neurochem. 2011 Jun;117(6):1066-74. doi: 10.1111/j.1471-4159.2011.07284.x. Epub 2011 May 13.

18.

Rational therapeutic approaches to progressive supranuclear palsy.

Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU.

Brain. 2010 Jun;133(Pt 6):1578-90. doi: 10.1093/brain/awq115. Epub 2010 May 14. Review.

PMID:
20472654
19.

Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.

Höllerhage M, Matusch A, Champy P, Lombès A, Ruberg M, Oertel WH, Höglinger GU.

Exp Neurol. 2009 Nov;220(1):133-42. doi: 10.1016/j.expneurol.2009.08.004. Epub 2009 Aug 13.

PMID:
19682988
20.

Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.

Escobar-Khondiker M, Höllerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, Höglinger GU.

J Neurosci. 2007 Jul 18;27(29):7827-37.

Supplemental Content

Loading ...
Support Center